Elevian is developing new medicines to promote recovery and regeneration. Its lead program is a recombinant protein to treat stroke in the days following the event, for which there are currently no viable treatments. By promoting regeneration, Elevian's medicines have the potential to treat and prevent many aging-associated diseases.
💸 Select investors:
Prime Movers Lab, Bold Capital Partners, The Longevity Fund, For Good Ventures, Lauder Partners